Fingolimod Teva: Uses, Dosage & Side Effects
An oral sphingosine 1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis in adults and adolescents
Fingolimod Teva is a prescription oral medication containing fingolimod hydrochloride 0.25 mg, used as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). As a sphingosine 1-phosphate (S1P) receptor modulator, fingolimod works by trapping lymphocytes in lymph nodes, reducing their migration into the central nervous system where they cause the inflammatory damage characteristic of MS. Fingolimod Teva is a generic equivalent of the originator product Gilenya and is taken as one capsule daily by mouth. Clinical trials have demonstrated that fingolimod significantly reduces relapse rates, delays disability progression, and decreases lesion activity on MRI compared with placebo and interferon beta-1a. First-dose cardiac monitoring is required due to transient heart rate effects.
Quick Facts: Fingolimod Teva
Key Takeaways
- Fingolimod Teva (fingolimod 0.25 mg) is an oral disease-modifying therapy that reduces relapse frequency and slows disability progression in relapsing forms of multiple sclerosis by preventing inflammatory lymphocytes from reaching the central nervous system.
- First-dose cardiac monitoring for at least 6 hours is mandatory because fingolimod can cause transient bradycardia and atrioventricular conduction delays; this effect diminishes with continued daily dosing.
- Pivotal clinical trials (FREEDOMS and TRANSFORMS) demonstrated a 54% reduction in annualized relapse rate versus placebo and a 52% reduction versus intramuscular interferon beta-1a, with significant MRI benefits.
- Fingolimod is contraindicated in pregnancy due to the risk of congenital malformations; women of childbearing potential must use effective contraception during treatment and for 2 months after stopping.
- Regular monitoring is required during treatment, including ophthalmic examinations for macular edema (at 3–4 months), liver function tests, complete blood counts, and periodic dermatological evaluations for skin malignancies.
What Is Fingolimod Teva and What Is It Used For?
Fingolimod Teva contains fingolimod hydrochloride as the active substance. Fingolimod is a first-in-class sphingosine 1-phosphate (S1P) receptor modulator that was originally derived from myriocin, a metabolite of the fungus Isaria sinclairii, which has been used in traditional Chinese medicine. After chemical modification and extensive pharmaceutical development, fingolimod was developed as a novel immunomodulatory agent with a unique mechanism of action distinctly different from other disease-modifying therapies for multiple sclerosis.
After oral administration and absorption, fingolimod undergoes phosphorylation by the enzyme sphingosine kinase 2 to form its active metabolite, fingolimod-phosphate. This active metabolite is a structural analogue of sphingosine 1-phosphate, a natural lipid signaling molecule that plays a critical role in regulating lymphocyte trafficking throughout the body. Fingolimod-phosphate binds with high affinity to four of the five known S1P receptor subtypes: S1P1, S1P3, S1P4, and S1P5. Its primary therapeutic mechanism involves functional antagonism of S1P1 receptors on lymphocytes.
Under normal physiological conditions, lymphocytes exit lymph nodes by following an S1P concentration gradient, with S1P1 receptor signaling being essential for this egress process. When fingolimod-phosphate binds to S1P1 receptors on lymphocytes, it initially activates the receptor but then causes its internalization and degradation from the cell surface. Without functional S1P1 receptors, lymphocytes cannot detect the S1P gradient and become sequestered within the lymph nodes. This results in a dose-dependent, reversible reduction in circulating lymphocyte counts, typically to approximately 20–30% of baseline values. Crucially, fingolimod preferentially retains CCR7-positive naïve T cells and central memory T cells in the lymph nodes, while effector memory T cells (which are important for immune surveillance against previously encountered pathogens) are less affected.
In the context of multiple sclerosis, this mechanism is therapeutically beneficial because the pathological inflammatory process in MS is driven by autoreactive lymphocytes that migrate from the peripheral blood across the blood-brain barrier into the central nervous system (CNS). Once in the CNS, these lymphocytes attack the myelin sheath surrounding nerve fibers, causing demyelination, axonal damage, and the formation of inflammatory lesions. By reducing the pool of circulating lymphocytes available for migration into the CNS, fingolimod diminishes the inflammatory assault on myelin and nerve tissue, thereby reducing relapses and slowing disability progression.
Beyond its effects on lymphocyte trafficking, fingolimod-phosphate also acts directly on S1P receptors within the CNS. S1P1 and S1P5 receptors are expressed on various CNS cell types, including astrocytes, oligodendrocytes, neurons, and microglia. Preclinical studies suggest that fingolimod may exert direct neuroprotective and remyelinating effects in the CNS by promoting oligodendrocyte survival, reducing astrogliosis, and modulating microglial activation. These CNS-specific effects may contribute to the overall clinical benefit observed in patients, although the relative contribution of peripheral versus central mechanisms remains an area of active research.
The efficacy and safety of fingolimod were established in three pivotal phase III clinical trials: FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis), FREEDOMS II, and TRANSFORMS (Trial Assessing Injectable Interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis). These trials collectively enrolled over 3,500 patients and demonstrated that fingolimod 0.25 mg significantly reduced the annualized relapse rate by 54% versus placebo (FREEDOMS), reduced disability progression, and decreased the number of new or enlarging T2 lesions and gadolinium-enhancing lesions on MRI.
Fingolimod Teva is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS) with relapses. In the European Union, fingolimod is also approved for pediatric patients aged 10 years and older with relapsing-remitting MS, based on results from the PARADIGMS trial which demonstrated superiority over interferon beta-1a in reducing relapse rates in this age group. The specific approved indications may vary between countries and regulatory jurisdictions, with some authorities reserving fingolimod for patients who have had an inadequate response to, or are unable to tolerate, one or more other disease-modifying therapies.
What Should You Know Before Taking Fingolimod Teva?
Contraindications
Fingolimod Teva must not be used in patients with known hypersensitivity to fingolimod or any of the excipients. It is contraindicated in patients who have experienced myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or New York Heart Association (NYHA) Class III/IV heart failure in the preceding 6 months. Patients with a history of or current second-degree Mobitz Type II or third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial heart block (unless the patient has a functioning pacemaker) must not receive fingolimod.
Additional contraindications include significant QT prolongation (QTc interval greater than 500 ms), concurrent treatment with Class Ia antiarrhythmic drugs (such as quinidine or procainamide) or Class III antiarrhythmic drugs (such as amiodarone or sotalol), severe active infections or active chronic infections (including hepatitis and tuberculosis), known active malignancies (except basal cell carcinoma of the skin), severe hepatic impairment (Child-Pugh Class C), and pregnancy or women of childbearing potential not using effective contraception.
Warnings and Precautions
Fingolimod requires careful patient selection and monitoring due to several important safety considerations. The most distinctive precaution relates to its cardiac effects. After the first dose, fingolimod causes a transient decrease in heart rate, with the maximum effect typically occurring within 6 hours. The average heart rate decrease is approximately 8 beats per minute, but some patients may experience more pronounced bradycardia. Additionally, fingolimod can cause first- and second-degree AV block, most commonly first-degree (prolonged PR interval). For this reason, all patients must undergo first-dose monitoring in a clinical setting equipped to manage symptomatic bradycardia.
All patients must be monitored for at least 6 hours after the first dose of fingolimod, with hourly pulse and blood pressure measurements. A 12-lead ECG must be obtained before the first dose and at the end of the 6-hour observation period. If the heart rate at 6 hours is at its lowest value since the first dose, monitoring must be extended for at least 2 additional hours. Extended monitoring is also required if the 6-hour ECG shows new-onset second-degree or higher AV block, or if the QTc interval is ≥ 500 ms. Patients who require pharmacological intervention for symptomatic bradycardia should be monitored overnight.
First-dose monitoring must also be repeated if treatment is interrupted for more than 14 consecutive days during the first 2 weeks of treatment, more than 7 consecutive days during weeks 3 and 4, or more than 1 day after the first month of treatment. This is because the cardiac chronotropic effect of fingolimod recurs upon re-initiation after treatment interruption.
Macular edema is another important safety concern. Fingolimod can cause macular edema, typically occurring within the first 3–4 months of treatment. Patients should undergo an ophthalmologic examination at baseline and again at 3–4 months after treatment initiation. Patients with a history of uveitis or diabetes mellitus are at increased risk and should have regular ophthalmologic evaluations throughout treatment. If macular edema develops, fingolimod should be discontinued, and the condition usually resolves after drug withdrawal.
Fingolimod may increase the risk of infections due to its immunomodulatory mechanism. In particular, patients are at increased risk of herpes virus infections, including disseminated herpes zoster, herpes simplex encephalitis, and varicella-zoster virus (VZV) reactivation. Cases of progressive multifocal leukoencephalopathy (PML) have been reported, primarily in patients with additional risk factors such as prior immunosuppressive therapy. Cryptococcal infections, including fatal cryptococcal meningitis, have also been reported. Patients should be monitored for signs and symptoms of infection throughout treatment.
Elevations in hepatic transaminases (ALT, AST, and GGT) have been observed during fingolimod treatment. Liver function tests should be performed before treatment initiation and periodically thereafter (at months 1, 3, 6, 9, and 12, then periodically). If ALT exceeds 5 times the upper limit of normal, more frequent monitoring should be instituted, including serum bilirubin and alkaline phosphatase. If ALT elevations are confirmed as significantly elevated, fingolimod should be discontinued.
Pregnancy and Breastfeeding
Fingolimod is contraindicated during pregnancy (Pregnancy Category X in the US; contraindicated per EMA labeling). Animal studies have demonstrated reproductive toxicity, including teratogenicity. In rats and rabbits, fingolimod caused fetal malformations, particularly of the heart (ventricular septal defect, persistent truncus arteriosus) and great vessels, at exposures similar to or lower than those achieved at the recommended human dose. Post-marketing reports have confirmed an increased risk of congenital malformations in infants exposed to fingolimod during pregnancy, with cardiovascular defects being the most commonly reported.
Women of childbearing potential must be informed of the serious risk to the fetus, must have a negative pregnancy test before starting treatment, and must use effective contraception during treatment and for at least 2 months after discontinuation of fingolimod. Given the long elimination half-life of fingolimod (6–9 days), the 2-month washout period ensures that the drug has been substantially cleared before any potential conception. If a woman becomes pregnant while taking fingolimod, the medication must be stopped immediately and the patient should receive appropriate counseling regarding the risk to the fetus.
Fingolimod is excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue breastfeeding or to discontinue fingolimod, taking into account the importance of the drug to the mother. The general recommendation is that women should not breastfeed during fingolimod treatment and for 2 months after the last dose.
Fingolimod has not been shown to affect male fertility in animal studies. However, given the teratogenic risk, healthcare providers should ensure that female patients of childbearing potential are using highly effective contraception before prescribing fingolimod. Acceptable methods include combined hormonal contraceptives, progestogen-only implants, intrauterine devices, or surgical sterilization. Counseling on contraception should be documented.
How Does Fingolimod Teva Interact with Other Drugs?
Major Interactions
The most clinically significant drug interactions with fingolimod involve medications that affect cardiac conduction or heart rate. When fingolimod is co-administered with beta-blockers (such as atenolol, metoprolol, or propranolol), the additive negative chronotropic effect can lead to clinically significant bradycardia. Similarly, non-dihydropyridine calcium channel blockers (diltiazem, verapamil) that slow AV conduction can potentiate the cardiac effects of fingolimod, potentially resulting in symptomatic bradycardia or AV block. If such combinations are medically necessary, extended cardiac monitoring beyond the standard 6-hour first-dose observation is recommended, typically with overnight monitoring in a facility capable of managing cardiac complications.
Class Ia antiarrhythmic drugs (quinidine, procainamide, disopyramide) and Class III antiarrhythmic drugs (amiodarone, dronedarone, sotalol, dofetilide) are contraindicated in combination with fingolimod due to the risk of torsade de pointes and other serious cardiac arrhythmias. These drugs can cause QT prolongation, and their combined use with fingolimod may result in additive cardiac conduction abnormalities with potentially fatal outcomes.
Co-administration with other immunosuppressant therapies (including natalizumab, alemtuzumab, ocrelizumab, mitoxantrone, cyclophosphamide, or long-term systemic corticosteroids) increases the risk of additive immunosuppression and serious infections. When switching from fingolimod to another immunosuppressant, the washout period and the prolonged reduction in lymphocyte counts must be considered to avoid overlapping immunosuppression. Conversely, when switching from a previous immunosuppressant to fingolimod, the duration of action and potential residual immune effects of the prior therapy must be assessed.
| Interacting Drug/Class | Severity | Mechanism | Clinical Recommendation |
|---|---|---|---|
| Beta-blockers (atenolol, metoprolol) | Major | Additive bradycardia and AV block | Extended cardiac monitoring; consider alternative MS therapy if stable on beta-blocker |
| Non-DHP calcium channel blockers (diltiazem, verapamil) | Major | Additive negative chronotropic and dromotropic effects | Overnight cardiac monitoring required at first dose |
| Class Ia/III antiarrhythmics (amiodarone, sotalol) | Contraindicated | Risk of torsade de pointes and severe conduction abnormalities | Do not co-administer; contraindicated |
| Digoxin | Moderate | Additive bradycardia | Monitor heart rate closely; consider cardiology consultation |
| Live attenuated vaccines | Major | Risk of infection from vaccine virus due to immunosuppression | Avoid during treatment and for 2 months after stopping |
| Other immunosuppressants (natalizumab, ocrelizumab) | Major | Additive immunosuppression; increased infection risk | Adequate washout period required when switching therapies |
| Ketoconazole (strong CYP4F2 inhibitor) | Moderate | Increased fingolimod and fingolimod-phosphate exposure by ~1.7-fold | Monitor for increased fingolimod effects; consider dose adjustment |
Minor Interactions
Fingolimod is primarily metabolized by CYP4F2, with a minor contribution from CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Co-administration with strong CYP4F2 inhibitors (such as ketoconazole) can increase blood levels of fingolimod and fingolimod-phosphate by approximately 1.7-fold. While this increase may not require dose adjustment in most patients, close monitoring for adverse effects (particularly cardiac and hepatic effects) is advisable.
Inactivated vaccines may have reduced efficacy when administered during fingolimod treatment due to the reduced lymphocyte count. Vaccination responses may be suboptimal, and serological testing to confirm adequate antibody responses should be considered, particularly for influenza and pneumococcal vaccines. If vaccination is planned, it should ideally be completed at least 2 weeks before starting fingolimod to allow for a full immune response.
Fingolimod does not significantly interact with common medications such as oral contraceptives, statins, proton pump inhibitors, or most antidepressants. No dose adjustment is required when fingolimod is co-administered with these agents. However, healthcare providers should review each patient’s complete medication list before starting fingolimod, as individual circumstances may warrant additional precautions.
What Is the Correct Dosage of Fingolimod Teva?
Adults
Standard Adult Dosing
The recommended dose is 0.25 mg (one capsule) once daily, taken orally with or without food. The capsule should be swallowed whole and not opened, crushed, or chewed. Fingolimod can be taken at any time of day, but it is advisable to take it at approximately the same time each day to maintain consistent blood levels. Steady-state blood concentrations of fingolimod and its active metabolite are reached within 1–2 months of once-daily dosing due to the long elimination half-life of 6–9 days.
The dose of 0.25 mg was selected based on extensive dose-finding studies that demonstrated it provides the optimal balance between efficacy and safety. Higher doses (1.25 mg and 5 mg) tested in early clinical trials showed similar or modestly greater efficacy but were associated with a higher incidence of adverse events, particularly cardiac effects and infections.
Children and Adolescents
Pediatric Dosing (Age 10 Years and Older)
Body weight > 40 kg: 0.25 mg once daily
Body weight ≤ 40 kg: 0.25 mg every other day, or lower-dose formulations where available (not applicable to this product)
Fingolimod is not recommended for children under 10 years of age due to insufficient safety and efficacy data. The pediatric indication is based on the PARADIGMS trial, which demonstrated a 82% relative reduction in annualized relapse rate compared with interferon beta-1a in patients aged 10–17 years.
Elderly Patients
Clinical experience with fingolimod in patients aged 65 years and older is limited, as clinical trials included few patients in this age group. No dose adjustment is required based on age alone. However, elderly patients should be treated with caution due to a higher likelihood of pre-existing cardiac conditions, hepatic impairment, and concomitant medications that may interact with fingolimod. The first-dose cardiac monitoring should be conducted with particular attention in this population.
Renal and Hepatic Impairment
No dose adjustment is required for patients with mild to moderate renal impairment. Fingolimod has not been studied in patients with severe renal impairment or those on dialysis; caution is advised in these patients. For patients with mild to moderate hepatic impairment (Child-Pugh Class A and B), no dose adjustment is necessary, although patients should be monitored closely for hepatic adverse effects. Fingolimod is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C).
Missed Dose
If a dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not take a double dose to make up for a missed dose. If treatment is interrupted for more than 14 consecutive days during the first 2 weeks, more than 7 consecutive days during weeks 3 and 4, or more than 1 day after the first month, first-dose monitoring procedures must be repeated when treatment is reinitiated. Patients should be counseled on the importance of treatment adherence and the specific rules regarding reinitiation after treatment gaps.
Overdose
In clinical trials, single doses up to 80 mg (320 times the recommended dose) and multiple doses up to 5 mg daily were tested. The primary risk in overdose is bradycardia, which may be severe and prolonged. In the event of an overdose, patients should be monitored continuously with ECG monitoring, as the heart rate decrease typically occurs within 1 hour of ingestion and can last for several hours. Standard supportive measures should be employed. Atropine or isoproterenol may be used to manage severe symptomatic bradycardia, although it should be noted that atropine may not be fully effective in reversing fingolimod-induced bradycardia. Fingolimod is not removed by dialysis or plasma exchange due to its large volume of distribution (approximately 1,200 L) and high protein binding (greater than 99.7%).
| Patient Group | Dose | Route | Special Considerations |
|---|---|---|---|
| Adults (18+ years) | 0.25 mg once daily | Oral | First-dose monitoring required; with or without food |
| Adolescents (10–17 years, >40 kg) | 0.25 mg once daily | Oral | First-dose monitoring; VZV antibody check required |
| Adolescents (10–17 years, ≤40 kg) | 0.25 mg every other day | Oral | Lower-dose formulations may be preferred where available |
| Elderly (65+ years) | 0.25 mg once daily | Oral | Extra cardiac vigilance; limited clinical data |
| Mild–moderate renal impairment | 0.25 mg once daily | Oral | No adjustment; not studied in severe impairment/dialysis |
| Mild–moderate hepatic impairment | 0.25 mg once daily | Oral | Monitor LFTs closely; contraindicated in Child-Pugh C |
What Are the Side Effects of Fingolimod Teva?
The safety profile of fingolimod has been characterized in clinical trials involving over 4,000 patients treated for up to 10 years in long-term extension studies, as well as through extensive post-marketing surveillance. The most frequently reported adverse reactions are related to fingolimod’s pharmacological activity, particularly its effects on the immune system and the cardiovascular system. Understanding the frequency and nature of these side effects is essential for informed decision-making by patients and healthcare providers.
Lymphopenia (a reduction in circulating lymphocyte counts) is an expected pharmacological effect of fingolimod rather than an adverse reaction, occurring in the vast majority of patients within the first month of treatment. Lymphocyte counts typically decrease to approximately 20–30% of baseline values and remain at this level during continued treatment. This reduction is reversible, and lymphocyte counts generally return to normal within 1–2 months after discontinuing fingolimod, although in some patients recovery may take longer.
Very Common (>1/10)
- Influenza viral infections
- Headache
- Cough
- Diarrhea
- Elevated liver enzymes (ALT increased)
- Back pain
- Lymphopenia (reduced lymphocyte count)
Common (1/10–1/100)
- Herpes virus infections (oral herpes, herpes zoster)
- Sinusitis, bronchitis
- Tinea infections (ringworm, athlete’s foot)
- Bradycardia (slow heart rate, especially at first dose)
- Atrioventricular block (first and second degree)
- Hypertension (elevated blood pressure)
- Macular edema
- Blurred vision
- Dizziness
- Migraine
- Asthenia (weakness/fatigue)
- Leukopenia (reduced white blood cell count)
- Eczema, alopecia (hair loss)
- Elevated GGT, elevated AST
- Weight loss
- Dyspnea (shortness of breath)
- Depression
Uncommon (1/100–1/1,000)
- Pneumonia
- Basal cell carcinoma (skin cancer)
- Squamous cell carcinoma of the skin
- Melanoma
- Lymphoma
- Nausea
- Posterior reversible encephalopathy syndrome (PRES)
- Thrombocytopenia (low platelet count)
- Peripheral neuropathy
Rare (<1/1,000)
- Progressive multifocal leukoencephalopathy (PML)
- Cryptococcal meningitis
- Kaposi sarcoma
- Hemophagocytic syndrome
- Severe prolonged bradycardia requiring intervention
- Immune reconstitution inflammatory syndrome (IRIS) after stopping
- Severe hepatic injury
Not Known (Frequency Cannot Be Estimated)
- Tumefactive multiple sclerosis lesions after stopping treatment
- Stevens-Johnson syndrome (very rare skin reaction)
- Disease rebound (severe MS relapse after discontinuation)
An important post-marketing concern relates to the phenomenon of disease rebound after fingolimod discontinuation. In some patients, stopping fingolimod can trigger a severe relapse of MS, sometimes with a more aggressive disease course than the patient experienced before treatment. This rebound phenomenon is thought to result from the rapid release of sequestered lymphocytes from lymph nodes, combined with the restoration of immune cell migration into the CNS. Healthcare providers should carefully plan the transition to alternative MS therapies when fingolimod is discontinued, ensuring that a new disease-modifying therapy is initiated promptly to minimize the gap in immunological protection.
Regarding hepatic effects, elevations in liver transaminases occur in approximately 8–14% of patients, with the increase typically appearing within the first 12 months of treatment. Most elevations are mild (less than 3 times the upper limit of normal) and resolve spontaneously without dose adjustment. However, patients should be counseled to report any symptoms suggestive of liver injury, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice.
Dermatological monitoring is recommended because fingolimod has been associated with an increased risk of skin malignancies, particularly basal cell carcinoma. Patients should be advised to limit sun exposure, use sunscreen, and undergo periodic dermatological examinations. Any suspicious skin lesion should be promptly evaluated and biopsied as appropriate.
Seek immediate medical attention if you experience: unexplained fever or persistent infection, vision changes or eye pain, severe headache with confusion or seizures, signs of liver injury (yellowing of the skin or eyes, dark urine), persistent unexplained nausea, new or changing skin lesions, or chest pain and irregular heartbeat. These may indicate serious adverse effects requiring urgent evaluation.
How Should You Store Fingolimod Teva?
Fingolimod Teva hard capsules should be stored at a temperature not exceeding 25°C (77°F). The capsules should be kept in the original blister packaging to protect them from moisture. There are no special storage requirements related to light sensitivity, but the capsules should not be exposed to excessive heat or direct sunlight for prolonged periods.
Do not freeze the capsules. If capsules have been accidentally frozen, they should not be used, as freezing may affect the integrity and bioavailability of the formulation. Always check the capsules before taking them; if the capsules appear damaged, discolored, or show signs of deterioration, they should not be taken, and a pharmacist should be consulted.
The medicine should be kept out of the sight and reach of children. Do not use Fingolimod Teva after the expiry date stated on the carton and blister pack (EXP). The expiry date refers to the last day of that month. Medicines should not be disposed of via wastewater or household waste. Patients should consult their pharmacist on how to dispose of medicines they no longer use, in accordance with local environmental regulations. These measures help to protect the environment.
What Does Fingolimod Teva Contain?
The active substance in Fingolimod Teva is fingolimod. Each hard capsule contains 0.25 mg of fingolimod, corresponding to 0.28 mg of fingolimod hydrochloride. Fingolimod hydrochloride is a white to off-white powder with a molecular formula of C19H33NO2·HCl and a molecular weight of 343.93 g/mol. It is freely soluble in water and most organic solvents.
The excipients (inactive ingredients) in the capsule contents include mannitol (a sugar alcohol used as a filler), hydroxypropylcellulose (a binder), hydroxypropyl betadex (a cyclodextrin used to enhance drug solubility and stability), and magnesium stearate (a lubricant used in the manufacturing process). The capsule shell is composed of gelatin, titanium dioxide (E171, a white colorant), and iron oxide yellow (E172, a colorant). The printing ink on the capsule contains shellac, propylene glycol, potassium hydroxide, and iron oxide black (E172).
None of the excipients in Fingolimod Teva contain lactose, gluten, or peanut-derived substances, making it suitable for patients with these specific dietary sensitivities. However, patients with known hypersensitivity to any of the listed excipients should not take this medication. The capsule shell does contain gelatin, which is derived from animal sources and may not be suitable for patients who avoid animal-derived products for religious, ethical, or dietary reasons.
Fingolimod Teva is a generic pharmaceutical product that has been approved by regulatory authorities based on demonstrated bioequivalence to the reference product Gilenya. This means that the generic product has been shown to deliver the same amount of active substance to the systemic circulation at the same rate and extent as the originator product, ensuring equivalent therapeutic effect and safety profile.
Frequently Asked Questions About Fingolimod Teva
Fingolimod Teva is used to treat relapsing forms of multiple sclerosis (MS) in adults, and in some regions in adolescents aged 10 years and older. It reduces the frequency of MS relapses and slows the progression of physical disability. It works by keeping certain immune cells (lymphocytes) trapped in the lymph nodes, preventing them from migrating into the brain and spinal cord where they cause inflammatory damage to nerve fibers.
Fingolimod can temporarily slow your heart rate and affect the electrical conduction system of the heart after the very first dose. This effect is caused by its action on S1P receptors in the cardiac conduction system. You will be monitored for at least 6 hours after taking the first capsule, including continuous ECG monitoring, pulse, and blood pressure measurements. This first-dose effect diminishes with continued daily use as the heart receptors adapt. If your treatment is interrupted for a specified period, the monitoring must be repeated when you restart.
Yes, Fingolimod Teva is a generic version of Gilenya. It contains the same active ingredient (fingolimod hydrochloride 0.25 mg), works through the same mechanism, and has been approved by regulatory authorities as bioequivalent to Gilenya. This means it delivers the same therapeutic effect and has the same safety profile. The primary difference is the manufacturer (Teva Pharmaceuticals vs. Novartis) and typically the price, as generic medications are generally more affordable than brand-name products.
Do not stop taking fingolimod without consulting your neurologist. When fingolimod is discontinued, lymphocyte counts gradually return to normal over 1–2 months. However, in some patients, abrupt discontinuation has been associated with a severe rebound of MS disease activity, including aggressive relapses that can be worse than the patient’s pre-treatment disease. For this reason, your neurologist will plan a careful transition to an alternative MS therapy when fingolimod is stopped, ensuring minimal gaps in immunological protection.
Live attenuated vaccines (such as MMR, varicella, yellow fever, and live nasal influenza vaccine) must be avoided during fingolimod treatment and for at least 2 months after stopping, because the suppressed immune system could allow the vaccine virus to cause infection. Inactivated vaccines (such as injectable influenza vaccine, COVID-19 vaccines, and pneumococcal vaccine) can be given, but the immune response may be weaker, meaning the vaccines may be less effective. Your doctor may check antibody levels after vaccination to confirm adequate protection.
Before starting treatment, you will need: a recent ECG and cardiac assessment, an eye examination (OCT to check for macular edema), blood tests including complete blood count, liver function tests, and varicella-zoster antibody status (with vaccination if negative, at least 1 month before starting treatment). During treatment, you will need regular monitoring: liver function tests at months 1, 3, 6, 9, and 12, then periodically; an eye examination at 3–4 months; regular blood counts; blood pressure monitoring; and periodic skin examinations for suspicious lesions.
References
- European Medicines Agency (EMA). Fingolimod – Summary of Product Characteristics. Available at: www.ema.europa.eu. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Gilenya (fingolimod) Prescribing Information. Reference ID: FDA-approved labeling. Last updated 2024.
- Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi:10.1056/NEJMoa0909494 (FREEDOMS trial).
- Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi:10.1056/NEJMoa0907839 (TRANSFORMS trial).
- Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–556.
- Chitnis T, Arnold DL, Banwell B, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–1027. doi:10.1056/NEJMoa1800149 (PARADIGMS trial).
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology. 2018;90(17):777–788. American Academy of Neurology (AAN).
- Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with relapsing-remitting multiple sclerosis. Mult Scler. 2018;24(2):96–120.
- Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883–897.
- World Health Organization (WHO). Model List of Essential Medicines – 23rd List, 2023. Geneva: WHO; 2023.
Editorial Team
Medical Content Team
Specialist physicians in neurology and clinical pharmacology with expertise in multiple sclerosis therapeutics and disease-modifying therapies.
Medical Review Board
Independent panel of board-certified neurologists and pharmacologists who verify all drug information against current EMA, FDA, and international guidelines.
Accessibility Team
Certified accessibility specialists ensuring WCAG 2.2 Level AAA compliance for all users, including those using assistive technologies.
Editorial Standards
All content follows the GRADE evidence framework with Level 1A evidence from systematic reviews and randomized controlled trials. No commercial funding.